{"abstract":"The National Institute of Allergy and Infectious Diseases, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the SUPPLEMENTARY INFORMATION section of this notice to TeraImmune, Inc. (\"TeraImmune\") located in Gaithersburg, Maryland, USA.","action":"Notice.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2022/01/25/2022-01330.html","cfr_references":[],"citation":"87 FR 3832","comment_url":null,"comments_close_on":"2022-02-09","correction_of":null,"corrections":[],"dates":"Only written comments and/or applications for a license which are received by the National Institute of Allergy and Infectious Diseases' Technology Transfer and Intellectual Property Office on or before February 9, 2022 will be considered.","disposition_notes":null,"docket_ids":[],"dockets":[],"document_number":"2022-01330","effective_on":null,"end_page":3832,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2022/01/25/2022-01330.xml","html_url":"https://www.federalregister.gov/documents/2022/01/25/2022-01330/prospective-grant-of-exclusive-patent-license-development-and-commercialization-of-regulatory-t-cell","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2022-01330?publication_date=2022-01-25","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2022-01-25/2022-01330/mods.xml","not_received_for_publication":null,"page_length":1,"page_views":{"count":156,"last_updated":"2026-08-23 20:15:04 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2022-01-25/pdf/2022-01330.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2022-01330.pdf?1643031929","publication_date":"2022-01-25","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2022/01/25/2022-01330.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"checked_regulationsdotgov_at":"2023-03-01T01:20:38Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":3832,"subtype":null,"title":"Prospective Grant of Exclusive Patent License: Development and Commercialization of Regulatory T-Cell Therapies for the Treatment of Multiple Sclerosis (MS)","toc_doc":"Development and Commercialization of Regulatory T-cell Therapies for the Treatment of Multiple Sclerosis","toc_subject":"Prospective Grant of Exclusive Patent License:\n","topics":[],"type":"Notice","volume":87}